Lung cancer drug sotorasib tested in chinese patients

NCT ID NCT07143513

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 39 times

Summary

This completed study looked at how safe sotorasib is for Chinese patients with a certain type of advanced lung cancer (KRAS G12C-mutated NSCLC). 102 patients who had already tried other treatments took sotorasib pills daily. Researchers tracked side effects and how long patients lived. The goal was to understand the drug's safety in a real-world setting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Boao Evergrande International Hospital

    Qionghai, Hainan, 571400, China

  • Boao Super Hospital

    Qionghai, Hainan, 571499, China

  • Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine Hainan Boao Research Hospital

    Qionghai, Hainan, 57400, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

sotorasib (a targeted cancer pill)

What this could lead to

If results are positive, this could confirm that sotorasib is safe and effective for Chinese patients with a specific type of lung cancer, supporting its use in this population.

What could go wrong

This is a completed real-world study, not a controlled trial, so results may be less reliable. Side effects like liver or lung problems are possible, and the drug only works for patients with a specific gene mutation.

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.